The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
bargain price for anyone thinking of getting in...... will rise again tomorrow
big sell just gone through? probably from a profit maker buying in last week at 1.75p lol
Akers Biosciences, Inc. ("ABI" or the "Company") US$3.2 Million Purchase Order - Revelar Free Radical Assay Akers Biosciences, Inc. (AIM:AKR), a leading designer and manufacturer of rapid diagnostic screening and testing products, has secured a purchase order totaling US$3,242,200 to manufacture and supply Revelar breath tubes to Pulse Health, LLC under the Company's Supply Agreement, as announced on 11 April 2011. This is the first purchase order under the Supply Agreement and manufacturing will commence immediately, from ABI's New Jersey facility, with the majority of this order expected to be fulfilled during 2011. Revelar provides the first accurate measurement system that both detects and measures aldehydes in exhaled breath. Aldehydes are known to be indicators of free radical activity that are thought to negatively impact or damage healthy cells throughout the human body. External factors, such as diet, activity, stress, chemicals and pollutants cause the body to produce excess free radicals that damage healthy cells. Studies show this may lead to heart disease, cancer and rapid aging. Millions of people in the developed world are consuming antioxidant supplements to counteract this process but neither patients, nor healthcare practitioners, have previously been able to accurately and efficiently determine whether a regime is working to improve patient health. The Revelar Assay, which consists of an electronic analyser and disposable breath tubes, instantly measures a patient's baseline aldehyde level and provides a numerical score, providing the first rapid, non-invasive way to measure the effectiveness of an antioxidant regimen and other interventions. Pulse Health, LLC, based in Portland, Oregon, is supplying The Revelar Assay to healthcare practitioners - particularly chiropractic centres - and health supplement producers and distributors initially in the USA and throughout the EU and then worldwide, where the sale of antioxidant products represents a multi-billion dollar annual market. Thomas A. Nicolette, President and Chief Executive of ABI, commented, "Pulse Health has identified a significant opportunity to provide an easy-to-use assay that empowers patients and healthcare practitioners with the knowledge to evaluate the effectiveness of a regime and adapt accordingly. We are extremely excited to be supplying this truly progressive test using ABI's proprietary breath condensate collection technology." Enquiries: Thomas A. Nicolette, President and CEO Tel. +1 856 848 8698 Antony Legge or Noelle Greenaway Daniel Stewart & Company plc (Nomad and Broker) Tel. +44 (0)20 7776 6550 Ben Simons M: Communications Tel. +44 (0)20 7920 2340 About Akers Biosciences, Inc. Akers Biosciences develops, manufactures, and supplies rapid, point of care screening and testing products designed to bring healthcar
Date Broker Recommendation Price Old target price New target price Notes 06 Dec Daniel Stewart Buy 3.63 7.00 7.00 Reiterates
Penny told Citywire: ‘Diagnostics is an attractive area. When you get the science right you can get very high margins. If this does not work, the company will need to secure more money but it now has time to bring out further products.’ And he has form in getting this area right. Penny has held a number of diagnostics peers including Immuno-Diagnostics Systems which floated at 75p and reached £9 after it successfully developed and commercialised its products. He also held BBI, which was eventually bought out at a premium by larger US rival Inverness Medical, as well as EKF and Tepnel Life Sciences, which were also bought out. Penny expects Akers to add 10-12 to its sales force to complement the one highly successful person already in place, but even if the selling does not lead to as many orders as he would like, Penny says there are plenty of others out there, such as EKF, who have the management expertise and track record to distribute such products. Further share price uplift could also come in the form of a buyout, from a larger rival bioscience peer.
sales target was $3.4m but they did $3.2m in one order... so should significantly be ahead of forecasts when final resutls are out
Penny tips the Heparin allergy testing product to bring in near-term cash. Indeed, it could be the 'game changer', he says. Another potential winner is Akers’ breath test for diabetes and the company has now had modest success selling some of the products into emerging markets. At its update last month, chief executive Thomas A. Nicolette revealed that sales of its commercialised diagnostic products has far exceeded market expectations in the year to the end of December 2010, adding that the group had received its first product order from Al Tadawi Medical in the Middle East for its Tri-Cholesterol check tests. The deal boosted revenues by some $1.5million. More good news came from the Heparin PF4 test, which produced revenue growth of 37% higher year on year. The encouraging news led house broker Daniel Stewart to reiterate its buy rating, and upgrade its 2011 full year sales estimates by $1 million to $3.4 million.
The group has a number of trials nearing completion and some that have already proved themselves, such as the Heparin HP4 allergy screening test. If its new clinical trial for a breath test to diagnose lung cancer comes off later this year it may have another winner in its stable but that would still involve trials with patients at all stages of the disease, for at least a further 12 months before it can produce any serious profits. Heparin PF4 could soon be producing near -erm profits, according to Penny. Game changer Penny has a strong track record of picking winners from the healthcare and diagnostics market and he sees the near-term prospect of cash generation from the Heparin PF4 product. This test screens for allergies to a widely used blood thinner, Heparin, which affects some 12 million people in the US. The study for this will commence within the next two to three months and Penny is excited about its prospects. Last week, Citywire AAA-rated Penny doubled his stake from 14,000 to 28,035,000 shares in the group, taking his ownership of the company to 16.61%. Penny has none in his L&G UK Alpha Trust as a minimum stake in there would need to be around 4%, but he has put the stock into his life product equivalent. Akers is currently trading at 3.75p but its broker Daniel Stewart has upgraded its target price from 6p to 10p and calculates some 82% upside following the placing. Penny told Citywire: ‘There is enough there to make this exciting. They have some products with big potential and are funded for the next 12 months
Its share price has risen as high as 25p on the back of the repeat order promise but have since falen back to languish at thearound the 3-4p mark over the last few months. In the aftermath, the group has found it more difficult to fund its continuing R&D but a successful £2 million raising this month has given it sufficient funding for its latest products, and moreover, the chance to successfully distribute them for the next 12 months.
The small cap universe holds a number of under-researched potential gems of this nature and Aim-listed Akers Biosciences could well be one. Akers Bio is a small US-based diagnostics provider which looks to replace what are traditionally onerous, expensive or invasive medical testing and screening processes with inexpensive, faster and non–invasive alternatives. The ability to effectively diagnose serious illness through something as simple as a breath test is an extremely attractive one to many. Some of Akers' products can do just this, through six separate science platforms which produce diagnostic kits to screen for conditions such as diabetes, asthma and lung cancer
Didn't expect that so soon...
mmm normally AKR news comes as a surprise. I think this rise is on the back of the recent announcement or maybe acquisition rumour. No broker upgrade either ? so maybe someone is sniffing around, trying to snap it up at a great price.
got a quote straight off 16944 shares @ 3.70p! thankyou for your reply and good luck to you also!
some research wondered if you can add anything im just in for a few hundred at 3.7p regards!!
is available......
to buy, i cant, its only negotiated, ie they have no shares..... to dummy sell 3.63p
in brief! whats the story here then please?
now. 40min tube juorney. lets see if 4p is hit by time i get to work
I bought here yesterday and added this morning. It's completely off-radar to many PIs I think, but upon doing a bit of research, I've now committed to a fair position, about 7% of my folio. Newsflow could be quite prolific over the coming weeks and months with a number of drugs undergoing trials/approvals. There's a good thread over on advfn that's worth a look if you've not seen it already. Still pretty quiet, but some quality posts.
another nice rise this week.
where is the discussion, do i have to do it all myself? lol
this isd going over 4p. my breakeven point. took its time! mms want your shares
spread closing again which is a great sign. someone wants these, and not a lot around!
take off with AKR!
online... mms very short of stock.